CAS 2230821-27-7
:Gefitinib-based PROTAC 3
Description:
Gefitinib-based PROTAC 3 is a chemical compound designed as a proteolysis-targeting chimera (PROTAC) that utilizes gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, as a ligand to selectively degrade target proteins. This compound is characterized by its dual functionality: it binds to the target protein of interest and recruits an E3 ubiquitin ligase, facilitating the ubiquitination and subsequent proteasomal degradation of the target. The structure of Gefitinib-based PROTAC 3 typically includes a linker that connects the gefitinib moiety to the E3 ligase ligand, which is crucial for its activity. The compound is primarily investigated for its potential in cancer therapy, particularly in cases where resistance to traditional EGFR inhibitors occurs. Its mechanism of action allows for the selective degradation of oncogenic proteins, potentially leading to improved therapeutic outcomes. As a relatively novel approach in targeted protein degradation, Gefitinib-based PROTAC 3 represents a significant advancement in the development of targeted cancer therapies.
Formula:C47H57ClFN7O8S
Synonyms:- Gefitinib-based PROTAC 3
- NTN21277
- NTN21277(Gefitinib-based PROTAC 3)
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 5 products.
Gefitinib-Based PROTAC 3
CAS:Formula:C47H57ClFN7O8SPurity:99%Color and Shape:SolidMolecular weight:934.5140Gefitinib-based PROTAC 3
CAS:<p>Gefitinib-PROTAC 3 degrades EGFR in cancer cells; DC50s: 11.7 nM (HCC827) and 22.3 nM (H3255).</p>Formula:C47H57ClFN7O8SPurity:97.29% - 98.25%Color and Shape:SolidMolecular weight:934.51
